JFBR vs TBPH vs AMZN vs INVA

For growth investors, Jeffs' Brands Ltd (JFBR) is the stronger pick with 36.

8% revenue growth year-over-year, versus 12. 1% for Theravance Biopharma, Inc. (TBPH). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Amazon. com, Inc. (AMZN) a "Buy" — based on 94 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus Amazon. com, Inc. at 37. 8x. On forward P/E, Theravance Biopharma, Inc. is actually cheaper at 6. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Innoviva, Inc. wins at 1. 15x versus Amazon. com, Inc. 's 1. 24x — a reasonable growth-adjusted valuation.

Over the past 5 years, Innoviva, Inc.

(INVA) delivered a total return of +94. 4%, compared to -100. 0% for Jeffs' Brands Ltd (JFBR). Over 10 years, the gap is even starker: AMZN returned +697. 8% versus JFBR's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus Amazon. com, Inc. 's 1. 51β — meaning AMZN is approximately 1098% more volatile than INVA relative to the S&P 500. On balance sheet safety, Jeffs' Brands Ltd (JFBR) carries a lower debt/equity ratio of 5% versus 37% for Amazon. com, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Jeffs' Brands Ltd (JFBR) is pulling ahead at 36.

8% versus 12. 1% for Theravance Biopharma, Inc. (TBPH). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -15. 0% for Theravance Biopharma, Inc.. Over a 3-year CAGR, JFBR leads at 28. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -87. 6% for Theravance Biopharma, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -72. 9% for TBPH. At the gross margin level — before operating expenses — TBPH leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Innoviva, Inc. (INVA) is the more undervalued stock at a PEG of 1. 15x versus Amazon. com, Inc. 's 1. 24x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Theravance Biopharma, Inc. (TBPH) trades at 6. 7x forward P/E versus 34. 8x for Amazon. com, Inc. — 28. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INVA: 65. 2% to $37. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Innoviva, Inc.

(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13)). Amazon. com, Inc. (AMZN) carries a higher beta of 1. 51 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INVA: +94. 9%, AMZN: +697. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (JFBR (Consumer Cyclical) and TBPH (Healthcare) and AMZN (Consumer Cyclical) and INVA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: JFBR is a small-cap high-growth stock; TBPH is a small-cap quality compounder stock; AMZN is a mega-cap quality compounder stock; INVA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.